PCSK9 Peptide Inhibitors

Science-Business eXchange
doi 10.1038/scibx.2014.134
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Are PCSK9 Inhibitors Cost Effective?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2018English

PCSK9 Inhibitors: When Statins Aren't Enough

Prescriber
Pharmacology
2017English

A Therapeutic Peptide Vaccine Against PCSK9

Scientific Reports
Multidisciplinary
2017English

PCSK9 Inhibitors: A Technology Worth Paying For?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2015English

Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice

Postgraduate Medicine
Medicine
2016English

Treatment Patterns and Patient Characteristics Among Early Initiators of PCSK9 Inhibitors

Vascular Health and Risk Management
2018English

A Review of Health Technology Assessments (HTA) of PCSK9 Inhibitors (PSCK9I)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Peptide-Based Anti-Pcsk9 Vaccines - An Approach for Long-Term LDLc Management

PLoS ONE
Multidisciplinary
2014English

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors

INNOVATIONS in pharmacy
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy